Bicycle Therapeutics plc (BCYC) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Bicycle Therapeutics plc (BCYC) closed at USD 3.51 on 2026-10-14, a change of -57.3 % over the past year, with a market capitalization of USD 251.32M.

Bicycle Therapeutics plc recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bicycle Therapeutics plc key figures

Previous close

USD 3.51 (2026-10-14)

1-year change

-57.3 %

Market cap

USD 251.32M

Enterprise value

USD -243.42M

P/E ratio (trailing)

-1.33

P/E ratio (forward)

-1.62

EPS (trailing)

-2.70

EPS (forward)

-2.22

PEG ratio

n/a

Price to book

0.49

Revenue growth

-78.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.64

Employees

288

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bicycle Therapeutics plc

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bicycle Therapeutics plc and compare it with other stocks.